- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ERASCA Aktie jetzt für 0€ handeln | |||||
| Fr | Erasca completes $258.8 million public offering of common stock | 1 | Investing.com | ||
| Fr | Erasca schließt Kapitalerhöhung über 258,8 Millionen US-Dollar ab | 1 | Investing.com Deutsch | ||
| Fr | Erasca, Inc.: Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | 1 | GlobeNewswire (USA) | ||
| Do | Erasca prices $225M stock offering at $10 per share | 1 | Seeking Alpha | ||
| Do | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | 101 | GlobeNewswire (Europe) | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| Mi | Erasca Announces $150 Million Public Offering; Stock Down | 1 | RTTNews | ||
| Di | Erasca-Aktie gibt nach geplanter Kapitalerhöhung über 150 Mio. US-Dollar nach | 13 | Investing.com Deutsch | ||
| Di | Erasca plans to raise $150 million in public stock offering | 1 | Investing.com | ||
| Di | Erasca, Inc.: Erasca Announces Proposed Public Offering of $150 Million of Common Stock | 133 | GlobeNewswire (Europe) | SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| Di | Erasca, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Di | Erasca (ERAS) Soars 42% on Bullish Rating, PT Upgrade | 9 | Insider Monkey | ||
| 15.01. | Erasca (ERAS) Hits Fresh High Anew as Firm Gets up to 267% PT Hike | 1 | Insider Monkey | ||
| 14.01. | Erasca (ERAS) Climbs to 3-Year High as Analyst Hikes PT by 83% | 2 | Insider Monkey | ||
| 13.01. | Erasca stock price target raised to $11 from $6 at H.C. Wainwright | 3 | Investing.com | ||
| 12.01. | Stifel raises Erasca stock price target to $10 on pipeline updates | 1 | Investing.com | ||
| 12.01. | Erasca meldet frühe Erfolge bei RAS-zielgerichtetem Krebsmedikament | - | Investing.com Deutsch | ||
| 12.01. | Erasca reports early responses with RAS-targeting cancer drug | 1 | Investing.com | ||
| 12.01. | Erasca, Inc.: Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones | 214 | GlobeNewswire (Europe) | Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for... ► Artikel lesen | |
| 12.01. | Erasca, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.01. | What's Going With Cancer Biotech Erasca Stock On Thursday? | 5 | Benzinga.com |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 98,10 | -0,05 % | Milliardenhoffnung: BioNTech greift mit Krebsforschung neu an: Goldman Sachs löst Kursschub mit optimistischem Onkologie-Ausblick aus | Die US-Investmentbank Goldman Sachs hat die Aktie von BioNTech deutlich hochgestuft. Statt auf das abklingende Impfstoffgeschäft konzentriert sich die Bewertung nun auf die wachstumsstarke Pipeline... ► Artikel lesen | |
| MODERNA | 41,225 | +0,01 % | Moderna erneut mit Kurssprung, auch BioNTech gibt Gas - was ist da los? | Die Aktie von Moderna ging am Mittwoch mit einem Plus von fast 16 Prozent aus dem Handel. Damit gelang der Sprung auf ein neues 52-Wochen-Hoch. Auch die Aktie des deutschen Konkurrenten BioNTech verzeichnete... ► Artikel lesen | |
| NOVAVAX | 7,763 | +0,01 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| ILLUMINA | 127,00 | -0,08 % | Illumina Gets Reimbursement For FDA-Approved TruSight Oncology Comprehensive Test, Stock Down | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Tuesday announced that the Centers for Medicare and Medicaid Services or CMS has granted reimbursement for the company's FDA-approved in vitro diagnostic... ► Artikel lesen | |
| NANOREPRO | 1,550 | -2,21 % | EQS-News: NanoRepro AG: Veränderungen im Aufsichtsrat | EQS-News: NanoRepro AG
/ Schlagwort(e): Personalie
NanoRepro AG: Veränderungen im Aufsichtsrat
19.01.2026 / 09:30 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer | SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,280 | 0,00 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| INFLARX | 0,844 | -1,80 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| DEFENCE THERAPEUTICS | 0,404 | +2,02 % | Defence Therapeutics Inc.: Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics | Montreal, Quebec--(Newsfile Corp. - January 21, 2026) - Defence Therapeutics Inc., (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company, today... ► Artikel lesen | |
| EDITAS MEDICINE | 1,860 | +2,00 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 5,802 | +0,94 % | BioCryst Pharmaceuticals, Inc.: BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema | RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially... ► Artikel lesen | |
| DYNAVAX | 13,275 | +1,07 % | Laufende Fusionskontrollverfahren: Sanofi S.A., Paris/FR; mittelbarer Erwerb eines Mehrheitsanteils und alleiniger Kontrolle über die Dynavax Technologies Corporation, Delaware/USA | Datum der Anmeldung:05.01.2026Aktenzeichen:B3-21/26Unternehmen:Sanofi S.A., Paris/FR; mittelbarer Erwerb eines Mehrheitsanteils und alleiniger Kontrolle über die Dynavax Technologies Corporation, Delaware/USAProduktmärkte:monovalenter... ► Artikel lesen | |
| IBIO | 1,950 | +2,09 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update | Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented... ► Artikel lesen |
ERASCA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 9,940 Euro und damit -2,74 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERASCA INC finden Sie auf Wallstreet Online.